GlassScriptPhysician profile
Christopher S Hiler
NPI 1336133701
$8,927.69
in general payments reported to CMS, 2019-2025
58 companies · $2,224 in 2025
The $2,224 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $833 · 2021: $1,450 · 2022: $1,468 · 2023: $820 · 2024: $1,060 · 2025: $2,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,387 · Travel and Lodging: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,387.35 |
| Travel and Lodging | $716.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,421.13 | 2021-2025 | Watchman, Watchman Flx, General - Therapies |
| Abbvie INC. | $901.90 | 2020-2025 | |
| Amgen INC. | $668.17 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $411.94 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $389.45 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $370.12 | 2019-2025 | |
| Lilly USA, LLC | $359.37 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.80 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $332.42 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $325.44 | 2021-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $303.58 | 2019-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $279.65 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Astrazeneca Pharmaceuticals LP | $226.59 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Sumitomo Pharma America, INC. | $226.06 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $177.08 | 2019-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hiler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.